OBJECTIVE: To evaluate the effects of iloprost infusion on the microcirculation in patients suffering from severe Raynaud's phenomenon secondary to systemic sclerosis. METHODS: Eight patients received a 7-hour infusion of iloprost for five consecutive days and then for one day 3 months later. The effects on vascular distensibility were evaluated by piezoelectric plethysmography before and after the treatment and at 2, 4 and 6 weeks. RESULTS: The beneficial effects on the peripheral microcirculation were statistically significant after five days of infusion (distensibility index: 0.18 +/- 0.01 vs 0.23 +/- 0.01, p < 0.002) and lasted for less than four weeks, whereas no difference (0.22 +/- 0.04 vs 0.24 +/- 0.02, p: ns) was seen after one day...
Background: The clinical efficacy of iloprost, a stable analogue of prostacyclin, in patients with R...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
BACKGROUND: Iloprost therapy for severe peripheral obstructive arterial disease (POAD) has demonstra...
OBJECTIVE: Iloprost is a stable prostacyclin analogue which has been shown to be effective in the sh...
Objectives: Iloprost plays an important role in the treatment of Raynaud\u2019s phenomenon (RP), but...
Objective: To assess the long-term effects of cyclic infusion of iloprost, a derivative of prostacyc...
Iloprost (ILO) is employed intravenously for the treatment of severe Raynaud phenomenon (RP) and dig...
Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a ...
Iloprost (ILO) is employed intravenously for the treatment of severe Raynaud phenomenon (RP) and dig...
Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a ...
Objective: To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability i...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
Objective: To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability i...
Objective: To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability i...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
Background: The clinical efficacy of iloprost, a stable analogue of prostacyclin, in patients with R...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
BACKGROUND: Iloprost therapy for severe peripheral obstructive arterial disease (POAD) has demonstra...
OBJECTIVE: Iloprost is a stable prostacyclin analogue which has been shown to be effective in the sh...
Objectives: Iloprost plays an important role in the treatment of Raynaud\u2019s phenomenon (RP), but...
Objective: To assess the long-term effects of cyclic infusion of iloprost, a derivative of prostacyc...
Iloprost (ILO) is employed intravenously for the treatment of severe Raynaud phenomenon (RP) and dig...
Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a ...
Iloprost (ILO) is employed intravenously for the treatment of severe Raynaud phenomenon (RP) and dig...
Objectives: to evaluate the clinical efficacy and the effects on the quality of life of Iloprost, a ...
Objective: To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability i...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
Objective: To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability i...
Objective: To identify the optimal dose of oral iloprost on the basis of efficacy and tolerability i...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
Background: The clinical efficacy of iloprost, a stable analogue of prostacyclin, in patients with R...
Objective. To identify the optimal dose of oral iloprost bn the basis of efficacy and tolerability i...
BACKGROUND: Iloprost therapy for severe peripheral obstructive arterial disease (POAD) has demonstra...